You are here: Industry Insights > immunotherapy

News List

Neurotrope Announces Publication of Phase 2 Alzheimer's Study contractpharma
December 18, 2018
Neurotrope Inc. announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease were published online in the Journal of Alzheimer's Disease.
BMS and Infinity trial immunotherapy combo in bladder cancer pharmaphorum
December 14, 2018
Bristol-Myers Squibb has broadened a collaboration with Infinity Pharmaceuticals as it seeks to find combinations that boost the potency of its cancer immunotherapy, Opdivo.
AZ begins liver cancer immunotherapy tie-up with AVEO pharmaphorum
December 14, 2018
AstraZeneca has announced a collaboration with US biotech AVEO oncology to investigate a potential cancer immunotherapy combination in liver cancer.
Certain brain tumours could respond to immunotherapy pharmaphorum
December 12, 2018
Some brain tumours may respond to immunotherapy after all, according to a new study.So far, brain tumours have been resistant to immunotherapy drugs because.....
Roche’s lung cancer combo treatment wins FDA approval expressbpd
December 11, 2018
The approval was based on results from a late-stage study, which showed the Tecentriq regimen helped patients with metastatic non-squamous non-small cell lung cancer (NSCLC)
Sartorius, Immunochina to advance immunotherapy development biospectrumasia
December 05, 2018
Immunochina will gain preferred access to SSB’s bioprocess technology platform for development, scale-up and production.
Sartorius and Immunochina Partner to Advance Immunotherapy Development pharmafocusasia
December 04, 2018
Sartorius Stedim Biotech (SSB), a leading international supplier of the biopharmaceutical industry, through its China affiliate, and Beijing-based Immunochina Pharmaceuticals....
How Chinese and Overseas Enterprises Catch the Next Immunotherapy Wave Yaohang
December 04, 2018
New breakthroughs are urgently needed in the tumor immunity field.
AstraZeneca’s immunotherapy fails in key lung cancer trial pharmaphorum
November 27, 2018
AstraZeneca’s immunotherapy combination including its checkpoint inhibitor drug Imfinzi has failed to improve overall survival in a first-line lung cancer trial – an indication where Merck & Co is enjoying huge sales success with Keytruda.
Obesity both feeds tumors and helps immunotherapy kill cancer worldpharmanews
November 15, 2018
A groundbreaking new study by UC Davis researchers has uncovered why obesity both fuels cancer growth and allows blockbuster new immunotherapies to work better against those same tumors. The paradoxical findings, published today in Nature Medicine, give c

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page